Back for its 13th annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2020 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors. The forum also features keynote speeches by KOL, about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities, and 20+ pitches by seed companies and during our Rising Stars session. We expect over 350 delegates to attend the event. The forum will provide a number of networking opportunities via our online One-2-One meeting systemwhich allows you to pre-book meetings with all the attendees at the dedicated meeting facilities. We anticipate more than 1700 face-to-face meetings to take place throughout 2 days.
Plenary Sessions will Include:
Global Outlook for Biopharma in 2020 Panel
Latest Trends in Private Equity & VC Panel
Pharma DealMakers Roundtable
CEO Vision Debate
China Partnering & Investment Panel
Israeli Innovators Panel
Early Stage Investor Roundtable
Rising Stars: Global Seed Session
Therapeutic Panels Include:
Advances in C&G Therapies Panel
Neuroscience BD&L Panel
Autoimmune & Inflammatory Diseases Panel
Oncology Advanced Therapies & Diagnostics Panel
Platform Technologies & Novel Therapeutics Panel
Oncology DealMaking Panel
Confirmed Keynote Speeches by:
“The Role of Optimism in Europe’s Health Start-up Ecosystem” by Joy Cürten, Head of Accelerator, EIT Health e.V.
"Recent trends in Global Pharma M&A and BD&L" by Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG
Confirmed Speakers & Chairs Include:
Adam Evertts, Senior Equity Research Analyst, LifeSci Capital, LLC
Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
Liat Hadad, Vice President Business Development, Sanara Ventures Ltd.
Lior Teitelbaum, CBO, FutuRx Ltd.
Lori Badura, VP, Head of BD Neurology and Immunology - Global BD & Alliance Management, EMD Serono
Lubor Gaal, SVP, Head of Europe, Locust Walk
Lynn Durham, Founder & CEO, STALICLA S.A.
Manuela Maronati, General Manager Europe, Atara Biotherapeutics, Inc.
Mark Altmeyer, Founder, Board Member, President & CEO, Arvelle Therapeutics GmbH
Markus Hosang, General Partner, BioMedPartners AG
Markus Kalousek, Head of Pharma Search & Evaluation, Global BD&L, Novartis International AG
Matthias Müllenbeck, Executive Director & Head Global Licensing & BD Enabling Technologies, Merck KGaA
Michael Altorfer, CEO, Swiss Biotech Association
Michael Crowley, Head BD for Pharma Research & Early Development, F. Hoffmann-La Roche Ltd.
Michael Huebner, New Venture Lead, Johnson & Johnson Innovation LLC
Michael Maguire, CEO, Avectas Ltd.
Miguel Forte, CEO, Bone Therapeutics SA
Mike Romanos, Co-Founder & CEO, Microbiotica Ltd.
Mirko Scherer, CEO, CoFeS China Ltd.
Naveed Siddiqi, Partner, Novo Holdings A/S
Nicholas Franco, EVP & Chief Business Development Officer, Actelion, a Janssen Pharmaceuticals Company of Johnson & Johnson
Olivier Reinhard, VP, Head of Execution for China & Emerging Markets, Sanofi
Pascal Neuville, CEO, Domain Therapeutics SA
Patrick Benz, Sr. Director Alliance Management, The Janssen Pharmaceutical Companies of Johnson & Johnson
Paul Hermant, Partner, Bird & Bird LLP
Peter Kash, Co-Founder & Vice-Chairman, TargImmune Therapeutics AG
Piotr Blaszczyk, CEO Fosun Pharma Europe, Fosun Pharmaceutical AG
Rachel Haurwitz, President & CEO, Caribou Biosciences, Inc.
Raphi Levy, CFO, Alpha Tau Medical Ltd.
Reagan Jarvis, Co-Founder & CEO, Anocca AB
Roberto De Ponti, Head of Corporate New Venture & Strategic Investments, Helsinn Investment Fund
Sarah Holland, Global Head of Licensing, Lonza AG
Sascha Bucher, Head of Global Transactions, Member of the Roivant Investment team & Head of the Basel Office, Roivant Sciences GmbH
Søren Møller, Managing Partner, Novo Seeds, Novo Holdings A/S
Sten Verland, Co-Founder & General Partner, Sunstone Life Science Ventures A/S
Stephanie Léouzon, Partner & Head of Europe, Torreya Partners LLP
Tal Gilat, CEO, Neurogenesis Ltd.
Thibaut Roulon, Investment Director, Life Sciences Investments, Bpifrance
Thilo Schroeder, Partner, Nextech Invest Ltd.
Tim Haines, Chairman & Managing Partner, Abingworth LLP
Tim Luker, VP, Emerging Technology & Innovation, Corporate BD, Eli Lilly and Company
Vanela Bushi, Director, Portfolio Strategy & Transactions, Syneos Health
Vishal Doshi, Founder & CEO, AUM Biosciences
Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.
Yuwen Liu, Founding Partner, BOHE Angel Fund
More TBA shortly...
Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business. Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures as well as access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and provide once again, opportunities for executive-level networking, deal-making and strategic partnering.
Presenters at the 13th ELSF Forum Include:
Make connections, engage in conversation, and exchange knowledge with key decision-makers eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at 13th Annual European Life Sciences CEO Forum is an effective way to gain leads, introduce new products and services, expand sales, and build relationships. Exhibition space is very limited - express your interest to secure the area.
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.
To learn more about presenting, exhibition or sponsorship opportunities, please contact: Silvia Kar on + 44 (0)203 463 4890 or by email: Silvia.
FINANCIAL, ADVISORY, INVESTORS ATTENDING: +ND Capital AbbVie Ventures Abingworth LLP Acceleris Capital Limited ACXIT Capital Management GmbH aescuvest international GmbH Aglaia BioMedical Ventures Alta Life Sciences Altitude Investment Management, LLC Andarix Pharmaceuticals Apollo Ventures ariadne-service GmbH ARTO AG Asklepios Advisors ATGN Consulting Banca del Ceresio Bank Julius Baer & Co. Ltd. Banque Profil de Gestion SA BB Pureos Bioventures Bellevue Asset Management AG Bergmann zur Hausen & Cie. GmbH Berlin Partner for Business and Technology GmbH BERNINA BioInvest Ltd BioGeneration Ventures BioMedPartners AG Bioqube Ventures BioScience Managers Pty Ltd. BioStart Consulting GmbH BOHE Angel Fund Bootstrap Europe Bpifrance Breslin AG BROTHERS & PARTNERS EUROPE Bryan, Garnier & Co Capital Grand Est Capricorn Partners NV CD3/CISTIM Claris Ventures CoFeS China Ltd. Coparion GmbH & Co. KG DDF Ventures B.V. Deepbridge Capital LLP Delin Ventures Ltd. Deutsche Bank E.Gutzwiller & Cie, Banquiers Earlybird Venture Capital Eclosion SA Edison Investment Research, Inc. Emerging Technology Partners, LLC (ETP) ErfindungsVerwertung AG (EVA) Ernst & Young AG European Investment Bank European Investment Fund FastVentures B.V. Ferghana Partners Fraser Finance LLP FutuRx Ltd. Genextra S.p.A. Gilde Healthcare Partners Gimv GL Capital Group GLSV GmbH Goetzpartners Securities GrowthCube Partners LLC H.C. Wainwright & Co., LLC Hadean Ventures HBM Partners AG Heal Capital HealthCare Royalty Partners High-Tech Gründerfonds Management GmbH IAG Italian Angels for Growth ICF Consult (Switz.) Ihang Equity Investment Indaco Venture Partners SGR SpA Industrifonden Inkef Capital B.V. Innogest Capital Inserm Transfert Initiative / Sofimac Inveready Asset Management IPF Partners Jefferies Joint Polish Investment Fund Kempen & Co KIZOO Technology Capital GmbH